Polio

Poliomyelitis ( ), commonly shortened to polio, is a vaccine-preventable infectious disease caused by the poliovirus.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 11 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Poliomyelitis ( ), commonly shortened to polio, is a vaccine-preventable infectious disease caused by the poliovirus. Approximately 75% of cases are asymptomatic; mild symptoms which can occur include sore throat and fever; in a proportion of cases more severe symptoms develop such as headache, neck stiffness, and paresthesia. These symptoms usually pass within one or two weeks.

A less common symptom is permanent paralysis, and possible death in extreme cases. Years after recovery, post-polio syndrome may occur, with a slow development of muscle weakness similar to what the person had during the initial infection. Polio occurs naturally only in humans.

It is highly infectious, and is spread from person to person either through fecal–oral transmission (e.g. poor hygiene, or by ingestion of food or water contaminated by human feces), or via the oral–oral route. Those who are infected may spread the disease for up to six weeks even if no symptoms are present.

The disease may be diagnosed by finding the virus in the feces or detecting antibodies against it in the blood. Poliomyelitis has existed for thousands of years, with depictions of the disease in ancient art. The disease was first recognized as a distinct condition by the English physician Michael Underwood in 1789, and the virus that causes it was identified in 1909 by the Austrian immunologist Karl Landsteiner.…

Poliomyelitis ( ), commonly shortened to polio, is a vaccine-preventable infectious disease caused by the poliovirus. Approximately 75% of cases are asymptomatic; mild symptoms which can occur include sore throat and fever; in a proportion of cases more severe symptoms develop such as headache, neck stiffness, and paresthesia. These symptoms usually pass within one or two weeks.

A less common symptom is permanent paralysis, and possible death in extreme cases. Years after recovery, post-polio syndrome may occur, with a slow development of muscle weakness similar to what the person had during the initial infection. Polio occurs naturally only in humans.

It is highly infectious, and is spread from person to person either through fecal–oral transmission (e.g. poor hygiene, or by ingestion of food or water contaminated by human feces), or via the oral–oral route. Those who are infected may spread the disease for up to six weeks even if no symptoms are present.

The disease may be diagnosed by finding the virus in the feces or detecting antibodies against it in the blood. Poliomyelitis has existed for thousands of years, with depictions of the disease in ancient art. The disease was first recognized as a distinct condition by the English physician Michael Underwood in 1789, and the virus that causes it was identified in 1909 by the Austrian immunologist Karl Landsteiner.

Major outbreaks started to occur in the late 19th century in Europe and the United States, and in the 20th century, it became one of the most worrying childhood diseases. Following the introduction of polio vaccines in the 1950s, polio incidence declined rapidly. , only Pakistan and Afghanistan remain endemic for wild poliovirus (WPV). Once infected, there is no specific treatment.

The disease can be prevented by the polio vaccine, with multiple doses required for lifelong protection. There are two broad types of polio vaccine; an injected polio vaccine (IPV) using inactivated poliovirus and an oral polio vaccine (OPV) containing attenuated (weakened) live virus.

Through the use of both types of vaccine, incidence of wild polio has decreased from an estimated 350,000 cases in 1988 to 30 confirmed cases in 2022, confined to just three countries. In rare cases, the traditional OPV was able to revert to a virulent form.

An improved oral vaccine with greater genetic stability (nOPV2) was developed and granted full licensure and prequalification by the World Health Organization in December 2023. )

Complications

Residual complications of paralytic polio often occur following the initial recovery process. Muscle paresis and paralysis can sometimes result in skeletal deformities, tightening of the joints, and movement disability. Once the muscles in the limb become flaccid, they may interfere with the function of other muscles.

A typical manifestation of this problem is equinus foot (similar to club foot). This deformity develops when the muscles that pull the toes downward are working, but those that pull it upward are not, and the foot naturally tends to drop toward the ground. If the problem is left untreated, the Achilles tendons at the back of the foot retract and the foot cannot take on a normal position.

People with polio that develop equinus foot cannot walk properly because they cannot put their heels on the ground. A similar situation can develop if the arms become paralyzed. In some cases the growth of an affected leg is slowed by polio, while the other leg continues to grow normally.

The result is that one leg is shorter than the other and the person limps and leans to one side, in turn leading to deformities of the spine (such as scoliosis). Osteoporosis and increased likelihood of bone fractures may occur.

An intervention to prevent or lessen length disparity can be to perform an epiphysiodesis on the distal femoral and proximal tibial/fibular condyles, so that limb's growth is artificially stunted, and by the time of epiphyseal (growth) plate closure, the legs are more equal in length. Alternatively, a person can be fitted with custom-made footwear which corrects the difference in leg lengths.

Other surgery to re-balance muscular agonist/antagonist imbalances may also be helpful. Extended use of braces or wheelchairs may cause compression neuropathy, as well as a loss of proper function of the veins in the legs, due to pooling of blood in paralyzed lower limbs.

Complications from prolonged immobility involving the lungs, kidneys and heart include pulmonary edema, aspiration pneumonia, urinary tract infections, kidney stones, paralytic ileus, myocarditis and cor pulmonale.

Post-polio syndrome

Between 25 percent and 50 percent of individuals who have recovered from paralytic polio in childhood can develop additional symptoms decades after recovering from the acute infection, notably new muscle weakness and extreme fatigue. This condition is known as post-polio syndrome (PPS) or post-polio sequelae.

The symptoms of PPS are thought to involve a failure of the oversized motor units created during the recovery phase of the paralytic disease. Contributing factors that increase the risk of PPS include aging with loss of neuron units, the presence of a permanent residual impairment after recovery from the acute illness, and both overuse and disuse of neurons.

PPS is a slow, progressive disease, and there is no specific treatment for it. Post-polio syndrome is not an infectious process, and persons experiencing the syndrome do not shed poliovirus.

Epidemiology

Major polio epidemics were unknown before the 20th century; up until that time, polio was an endemic disease worldwide. Mothers who had survived polio infection passed on temporary immunity to their babies in the womb and through breast milk. As a result, an infant who encountered a polio infection generally suffered only mild symptoms and acquired a long-term immunity to the disease.

With improvements in sanitation and hygiene during the 19th century, the general level of herd immunity in the population declined; this provided circumstances where epidemics of polio became frequent. In the first half of the 20th century, it is estimated that epidemic polio killed or paralysed over half a million people every year.

Following the widespread use of poliovirus vaccine in the mid-1950s, new cases of poliomyelitis declined dramatically in many industrialized countries. Efforts to completely eradicate the disease started in 1988 and are ongoing.

Circulating vaccine-derived polioviruses

The oral polio vaccine, while highly effective, has the disadvantage that it contains a live virus which has been attenuated so that it cannot cause severe illness. The vaccine virus is excreted in the stool, and in under-immunized communities it can spread from person to person. This is known as circulating vaccine-derived poliovirus (cVDPV) or more simply as variant poliovirus.

With prolonged transmission of this kind, the weakened virus can mutate and revert to a form that causes illness and paralysis. Cases of cVDPV now exceed wild-type cases, making it desirable to discontinue the use of the oral polio vaccine as soon as safely possible and instead use other types of polio vaccines.

Eradication

A global effort to eradicate polio – the Global Polio Eradication Initiative – began in 1988, led by the World Health Organization, UNICEF, and The Rotary Foundation. Polio is one of only two diseases currently the subject of a global eradication program, the other being Guinea worm disease.

So far, the only diseases completely eradicated by humankind are smallpox, declared eradicated in 1980, and rinderpest, declared eradicated in 2011. In April 2012, the World Health Assembly declared that the failure to completely eradicate polio would be a programmatic emergency for global public health, and that it "must not happen".

These efforts have hugely reduced the number of cases; from an estimated 350,000 cases in 1988 to a low of 483 cases in 2001, after which it remained at a level of about 1,000–2000 cases per year for a number of years. By 2015, polio was believed to remain naturally spreading in only two countries, Pakistan and Afghanistan, although it continued to cause outbreaks in other nearby countries due to hidden or re-established transmission.

Global surveillance for polio takes two forms. Cases of acute flaccid paralysis (AFP) are tested for the presence and type of poliovirus. In addition, environmental and wastewater samples are tested for the presence of poliovirus - this is an effective method of detecting circulating virus which has not given rise to severe symptoms.

Here is a summary of both wild polio (WPV) and variant polio (cVDPV) prevalence over the years shown: In 2019, 147 cases of WPV1 were noted in Pakistan and 29 in Afghanistan. None were reported elsewhere in the world. cVDPV was detected in 19 countries with 378 confirmed cases. In 2020, 84 WPV1 cases were reported in Pakistan along with 56 in Afghanistan.

32 countries reported cVDPV detection, and there were 1,103 cVDPV cases. In 2021, there were just six confirmed cases of wild poliovirus — one in Pakistan, four in Afghanistan, and one in Malawi. The case in Malawi, the country's first in almost three decades and the first in Africa in five years, was seen as a significant setback to the eradication effort.

23 countries detected cVDPV, with 698 cases. In 2022, there were 30 confirmed cases of WPV1 reported to WHO, with two cases in Pakistan and 20 Afghanistan respectively, while eight non-endemic cases were recorded in Mozambique, the first cases in the country since 1992. The Mozambique cases derived from the strain of Pakistani origin that caused two confirmed cases in Malawi in 2021.

24 countries detected cVDPV, with 881 cases. In 2023, twelve cases of WPV1 were reported, six each in Afghanistan and Pakistan. 32 countries reported cVDPV, with 524 cases.

Research

Since 2018, Global Polio Eradication Initiative (GPEI) has coordinated efforts both to eliminate polio and to research means of improving surveillance and prevention. At the peak of its work, the programme directly employed 4000 people across 75 countries and managed a budget of nearly U.S. $1 billion. , the GPEI had raised 18 billion dollars in funding, with annual contributions around 800 million to 1 billion dollars.

Around 30% of the funding came from the Gates Foundation 30% from developed governments, 27% from countries at risk of polio, and the rest was made up of donations from nonprofits, private funders, and other foundations. The GPEI has identified six directions for continuing research: Optimizing oral polio vaccine efficacy Developing affordable inactivated polio vaccine Managing risks associated with vaccine-derived polioviruses and vaccine-associated paralytic polio (including OPV cessation) Antivirals Polio diagnostics Surveillance research Even if polio can be eliminated from the world population, vaccination programs should continue for at least ten years.

The retention of live poliovirus samples in laboratories and vaccine manufacturing facilities (which carry a risk of escape of the virus) should progressively be reduced. To support these two objectives, vaccines are under development which either utilise a virus-like particle, or which derive from a modified virus which cannot reproduce in a human host.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1378810227 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

23 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.